CT Attorney General Initiates Lawsuit Against Stamford's Purdue Pharma for Role in National Opioid Crisis
/Connecticut Attorney General George Jepsen has initiated a lawsuit against Stamford-based Purdue Pharma and several current and former members of Purdue's management and board of directors alleging that they designed, financed and waged a pervasive and aggressive campaign to mislead doctors and patients, claiming that prescription opioid medications manufactured and marketed by the company were safe and effective and strategically downplaying risks of addiction that they knew were inherent in their opioid products.
The state alleges that Purdue "peddled a series of falsehoods" to push patients toward its opioids, reaping massive profits from sales while opioid addiction skyrocketed to the crisis level that is currently impacting Connecticut and states across the country.
"For a number of months, Connecticut and our multistate partners have been engaged in intensive negotiations with opioid manufacturers and distributors in the hope of resolving potential legal claims in a way that would avoid protracted litigation and would bring opioid treatment resources to those who are desperately in need," said Attorney General Jepsen. Jepsen, who leaves office next month, currently serves as part of the leadership of a multistate coalition of attorneys general who are investigating opioid manufacturers and distributors. "I expect those negotiations to continue, and I remain hopeful they will bring a resolution that helps to address this ongoing crisis."
In Connecticut, 1,038 people died of accidental drug overdoses in 2017, the vast majority from opioid-related overdoses. The Connecticut Office of the Chief Medical Examiner has projected that 1,030 more people will die of overdoses in 2018. From 2013 to 2016, Connecticut experienced a fourfold increase in deaths from prescription opioid overdoses, and the estimated economic cost of the opioid epidemic in Connecticut in 2016 was $10.27 billion. Nationwide from 2002-2017 there was a 4.1-fold increase in the total number of deaths involving opioids, according to the National Institute on Drug Abuse. 
The Attorney General said that Purdue Pharma “has not demonstrated to me that it is serious about addressing the states' very real allegations of misconduct and coming to a meaningful settlement. It is my hope that, in filing this lawsuit at this time, Connecticut can assist in the collective effort to hold this company and responsible individuals accountable.
Jepsen said the state alleges that “Purdue knowingly put its own exorbitant profits first when it purposefully and systematically misled doctors by not just downplaying the terrible risks of addiction, but by forcefully asserting that opioid products were safe, that the risk of addiction was low, and that patients experiencing symptoms of addiction should actually be prescribed higher and greater doses of Purdue's opioid drugs. We allege that this behavior was endorsed and promoted by the highest leadership of the company and that it was in violation of Connecticut law."
The state alleges that Purdue misinformed patients and doctors to get more and more people taking its premier opioid drug, OxyContin, and its two other opioid medications, Hysingla and Butrans.
The lawsuit will be filed in Superior Court in Hartford. It alleges four counts of violations of the Connecticut Unfair Trade Practices Act and seeks damages, civil penalties, forfeiture of ill-gotten profits and restitution as well as permanent injunctive and other relief. The suit indicates that Purdue allegedly:
- led patients and doctors to believe that opioids were safe to treat even minor pain, and that patients could and should take higher and more dangerous doses.
- sent sales representatives to doctors' offices, clinics, pharmacies and hospitals in Connecticut to make deceptive sales pitches about opioid drugs;
- rewarded high-prescribing doctors with attention, meals, gifts and money; and
- awarded prizes and bonuses to sales representatives who generated the most opioid prescriptions.
The company did not tell doctors that higher doses of opioids carried heightened risk of addiction, overdose and death, the state alleges, and the company funded and distributed publications that misrepresented the addictive nature of prescription opioids and made claims that were not supported by scientific evidence.
The state further alleges that Purdue promoted the idea of "pseudoaddiction," suggesting that patients who appeared to be addicted were instead receiving inadequate doses and needed more prescription opioid drugs.
In addition to the company, the state's lawsuit names current and former board members as defendants, alleging that they tracked sales representatives and oversaw the tactics used to push opioid drugs. The individual defendants include: Richard Sackler, Jonathan Sackler, Mortimer D.A. Sackler, Kathe Sackler, Ilene Sackler Lefcourt, Beverly Sackler, David Sackler, Theresa Sackler, Cecil Pickett, Paulo Costa, Ralph Snyderman, Frank Peter Boer and Judy Lewent. The lawsuit also names past CEOs John Stewart and Mark Timney as defendants.






t have increased as much in comparison to other states, but isn’t the real question, ‘Why is it increasing at all?’” Luis Perez, president and CEO of
The analysis, by the financial services website WalletHub, was based on 40 key indicators of livability, ranging from housing costs to school-system quality to restaurants per capita. The indicators were grouped into five categories – affordability, economic health, education & health, safety, and quality of life.
The survey revealed that residents are not satisfied with the current health care system: 80 percent agree or strongly agree that “the system needs to change.” When given more than 20 options, they focused on the high prices charged by industry players, citing most frequently as a “major reason” for high health care costs:
The 40-page report, developed by The Child Health and Development Institute of Connecticut (CHDI), a subsidiary of the Children’s Fund of Connecticut, in partnership with the national Center for School Mental Health at the University of Maryland, provides a framework for policymakers and school districts interested in improving outcomes by addressing the mental health and trauma needs of students. The report indicates that “in a typical classroom of 25 students, approximately five will meet criteria for a mental health disorder but most of them are not receiving appropriate mental health treatment or support. Among those who do access care, approximately 70 percent receive services through their schools.”
“Approaching student mental health with a comprehensive lens that integrates health promotion, prevention, early intervention, and more intensive treatments leads to better school, student and community outcomes," said Dr. Sharon Hoover, Co-Director of the Center for School Mental Health at the University of Maryland and lead author of the report.
The personal-finance website WalletHub compared the largest U.S. cities – including at least two from each state - across 31 key indicators of disability-friendliness. The data set ranges from wheelchair-accessible facilities per capita to rate of workers with disabilities to quality of public hospital system. The 31 indicators were grouped into three categories: Economy, Quality of Life and Health Care.
“Bridgeport has one of the lowest number of wheelchair accessible art, entertainment and recreational establishments per capita, and a large number of older buildings with little to no access for disabled residents," Gonzalez said.

The